Moreover, KRAS mutations have been shown to alter amino acids, fatty acids, and nucleotide biosynthesis in cancer cells, further highlighting the role of oncogenic mutations in promoting drug resistance across various tumor types [182]. Here, KRAS is linked to neoplasm.